Metsera, Inc. Common Stock

NASDAQ:MTSR USA Biotechnology
Market Cap
$7.41 Billion
Market Cap Rank
#3198 Global
#2135 in USA
Share Price
$70.50
Change (1 day)
+0.00%
52-Week Range
$13.08 - $83.18
All Time High
$83.18
About

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to re… Read more

Metsera, Inc. Common Stock (MTSR) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of June 2025: -0.131x

Based on the latest financial reports, Metsera, Inc. Common Stock (MTSR) has a cash flow conversion efficiency ratio of -0.131x as of June 2025.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-58.96 Million) by net assets ($449.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Metsera, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2024)

This chart illustrates how Metsera, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Metsera, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Metsera, Inc. Common Stock ranked by their cash flow conversion efficiency.

Annual Cash Flow Conversion Efficiency for Metsera, Inc. Common Stock (2022–2024)

The table below shows the annual cash flow conversion efficiency of Metsera, Inc. Common Stock from 2022 to 2024.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 $287.35 Million $-100.04 Million -0.348x +3.11%
2023-12-31 $98.50 Million $-35.39 Million -0.359x -154.40%
2022-12-31 $-813.00K $-537.00K 0.661x --